EQS-News
Mainz Biomed Presents ColoAlert at UDH Congress 2024: Leading the Way in Evidence-Based Cancer Screening Innovations
- Mainz Biomed presents ColoAlert at UDH Congress 2024
- Leading in evidence-based cancer screening innovations
- Focus on bridging scientific research with healthcare practices
Issuer: Mainz BioMed N.V. / Key word(s): Miscellaneous Mainz Biomed Presents ColoAlert at UDH Congress 2024: Leading the Way in Evidence-Based Cancer Screening Innovations |
BERKELEY, US – MAINZ, Germany – March 12th 2024 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a leader in molecular genetics diagnostic solutions for early cancer detection, is proud to announce its upcoming participation at the 39th UDH Congress 2024, taking place on March 16th & 17th in Fellbach, Germany. One of the main focus topics for this year’s event, organized by the German Complementary Medicine Association (Union Deutscher Heilpraktiker, Landesverband Baden-Württemberg), is the gut and its significance in the manifestation of diseases.
Mainz Biomed’s showcase at the UDH Congress underscores the Company’s dedication to bridging the latest in scientific research with the wide spectrum of healthcare practices. Mainz Biomed’s engagement reflects a deep respect for the diverse methodologies within the healthcare community, emphasizing the commitment to contributing evidence-based, innovative solutions like ColoAlert.
ColoAlert, Mainz Biomed’s flagship product, is a testament to the Company’s mission, providing a highly accurate, easy-to-use, at-home colorectal cancer (CRC) screening kit. Its advanced tumor DNA analysis technology significantly improves early detection rates, a crucial factor in effective CRC management. By presenting ColoAlert at the UDH Congress, Mainz Biomed highlights the role of cutting-edge molecular diagnostics in enhancing comprehensive health strategies, demonstrating the synergy between technological innovation and patient-centric care.
This initiative is part of Mainz Biomed’s broader strategy to foster collaboration and knowledge exchange across the health sector. The Company aims to elevate the standard of care and advocate for the health and well-being of individuals through science-backed solutions.
For more details on Mainz Biomed’s participation in the UDH Congress and to learn about the Company’s innovative diagnostic solutions, please visit Mainz Biomed’s official website at mainzbiomed.com.